Hyperphenylalaninemia Clinical Presentation
- Author: Georgianne L Arnold, MD; Chief Editor: Bruce Buehler, MD more...
An abnormal newborn screen is the most common history in patients with hyperphenylalaninemia. Infants are screened for elevated phenylalanine in every US state and in Puerto Rico. Several other countries also have established screening programs.
Affected individuals missed by screening may have mild-to-moderate performance deficits, depending on the degree of phenylalanine elevation.
Measurable IQ deficits can be seen at phenylalanine levels in the hyperphenylalaninemia range, particularly as levels reach the teens. At phenylalanine levels near 20 mg/dL, phenylketonuria (PKU)-like symptoms may emerge, including more pronounced developmental abnormalities, eczema, and vomiting. Preliminary evidence indicates milder attention and organizational problems may arise when levels exceed 6 mg/dL.
Most children have few abnormal findings on physical examination.
Some physical stigmata of PKU may be present in individuals who have phenylalanine levels near 20 mg/dL. PKU-like symptoms include eczema and fair hair and skin coloring.
Genetic defects in phenylalanine hydroxylase cause most cases of hyperphenylalaninemia. In a few cases, defective synthesis or recycling of the biopterin cofactor is the cause (see Tetrahydrobiopterin Deficiency).
In some children with mild enzyme deficits, excessive protein intake may elevate phenylalanine levels to a range requiring treatment. The problem may resolve when protein intake is reduced to more ordinary levels. For example, infants with nonphenylketonuric hyperphenylalaninemia who consume excessive infant formula (60-70 oz/d or 1800-2100 mL/d) may demonstrate phenylalanine levels exceeding 10-12 mg/dL. Levels may fall when formula intake is restricted to 32-40 oz/d.
Prick BW, Hop WC, Duvekot JJ. Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies. Am J Clin Nutr. 2012 Feb. 95(2):374-82. [Medline].
Mak CM, Ko CH, Lam CW, et al. Phenylketonuria in Hong Kong Chinese: a call for hyperphenylalaninemia newborn screening in the Special Administrative Region, China. Chin Med J (Engl). 2011 Aug. 124(16):2556-8. [Medline].
Crujeiras V, Aldámiz-Echevarría L, Dalmau J, Vitoria I, Andrade F, Roca I, et al. Vitamin and mineral status in patients with hyperphenylalaninemia. Mol Genet Metab. 2015 Aug. 115 (4):145-50. [Medline].
Ten Hoedt AE, Hollak CE, Boelen CC, et al. "MY PKU": increasing self-management in patients with phenylketonuria. A randomized controlled trial. Orphanet J Rare Dis. 2011 Jun 27. 6:48. [Medline]. [Full Text].
Burton BK, Grange DK, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis. 2007 Oct. 30(5):700-7. [Medline].
Matalon R, Michals-Matalon K, Koch R, Grady J, Tyring S, Stevens RC. Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Mol Genet Metab. 2005 Dec. 86 Suppl 1:S17-21. [Medline].
Sarkissian CN, Gamez A, Wang L, et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc Natl Acad Sci U S A. 2008 Dec 30. 105(52):20894-9. [Medline]. [Full Text].
Berlin CM, Levy HL, Hanley WB. Delayed increase in blood phenylalanine concentration in phenylketonuric children initially classified as mild hyperphenylalaninemia. Screening. 1995. 4:35-39.
Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev. 1997. 62(4):i-v, 1-208. [Medline].
Fisch RO, Matalon R, Weisberg S, Michals K. Phenylketonuria: current dietary treatment practices in the United States and Canada. J Am Coll Nutr. 1997 Apr. 16(2):147-51. [Medline].
Gassio R, Artuch R, Vilaseca MA, et al. Cognitive functions in classic phenylketonuria and mild hyperphenylalaninaemia: experience in a paediatric population. Dev Med Child Neurol. 2005 Jul. 47(7):443-8. [Medline].
Scriver CR, Kaufman S, Eijsensmith RC. The hyperphenylalaninemias. The Metabolic and Molecular Bases of Inherited Disease. 1995. Vol 1: 1015-76.
Procházková D, Jarkovský J, Haňková Z, Konečná P, Benáková H, Vinohradská H, et al. Long-term treatment for hyperphenylalaninemia and phenylketonuria: a risk for nutritional vitamin B12 deficiency?. J Pediatr Endocrinol Metab. 2015 Nov 1. 28 (11-12):1327-32. [Medline].